Product analysis
Udo's Oil 3-6-9 Blend brings together several omega fats in a formula that appears well aligned with its intended use. Unspecified oil forms limit a direct comparison of ingredient quality.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
Oil forms are unspecified throughout the ingredient disclosure. Their relative quality therefore remains difficult to compare.
Ingredient Transparency63
The listed amounts are disclosed. Missing oil-form details limit a full comparison of what each serving contains.
Value For Money58
Omega-6 and omega-9 compare favorably on price. Omega-3 value remains uncertain, leaving the complete blend harder to judge.
Customer Satisfaction75
Customer feedback is generally positive across several hundred ratings. Those ratings describe satisfaction rather than proving health benefits.
Product Focus78
The formula remains concentrated on one intended goal. Its alignment with that purpose appears encouraging.
- Format
Softgel - Container
- 90 Softgel(s)
- Per serving
- $0.58
- Also available
Udo's Oil 3-6-9 Blend$52.18- Customer rating
- 4.6 · 576 ratings
Goals
Omega-3 is counted toward skin-barrier lipids in the saved findings. The supplied human evidence concerns a specific purified EPA preparation and UV-response measures, rather than a general skin benefit from mixed omega-3. The declared amount contributes to the saved comparison, but unresolved composition and preparation limit transfer of those results. Flax's presence remains unresolved, so flaxseed-oil trial findings cannot be assigned to this serving.
How this product is rated for Skin Health
Ingredient fit94
Goal fit
Dose adequacy
Pathways45
Depth
Breadth
Evidence78
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Calories | 20 Calorie(s) | |
Total Fat | 2 Gram(s) | |
Omega-3 Fatty Acids | 840 mg | |
Omega-6 Fatty Acids | 420 mg | |
Omega-9 Fatty Acids | 350 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability85
Oil Source & Form Quality
Extraction & Processing Method
Oxidation & Stability Protection
Dose, Safety & Label Transparency85
Omega-9 Potency per Serving
Label Transparency & Disclosure
Value70
Price per 100mg Omega-9
How this ingredient is rated
Active Ingredient Quality & Bioavailability4
Omega-6 Source & GLA Content
Extraction Method & Purity
Dose, Safety & Label Transparency57
Omega-6 Potency vs. Median
Fatty Acid Profile Transparency
Value80
Price Per Serving Efficiency
How this ingredient is rated
Active Ingredient Quality & Bioavailability24
Molecular Form & Absorption Potential
Source Purity & Oxidative Protection
Dose, Safety & Label Transparency15
EPA & DHA Label Specificity
Active Ingredient Concentration
Third-Party Purity Verification
Value0
Price per 1000mg of EPA+DHA
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Dietetic intervention in psoriatic arthritis: the DIETA trial.
- Omega-3 fatty acid supplement skin cancer prophylaxis in lung transplant recipients: A randomized, controlled pilot trial.
- Clinical and metabolic response to flaxseed oil omega-3 fatty acids supplementation in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.
- Treatment of hard-to-heal wounds in ischaemic lower extremities with a novel fish skin-derived matrix.
- Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers.
- Psychosocial Burden in People with Atopic Dermatitis: Effects of a Substance-Free Basic Skincare in a Randomized Health Care Study.
- Abnormalities in epidermal lipid metabolism in patients with atopic dermatitis.
- Maternal plasma phosphatidylcholine fatty acids and atopy and wheeze in the offspring at age of 6 years.
- Plasma omega-3 and omega-6 concentrations and risk of cutaneous basal and squamous cell carcinomas in Australian adults.
- Maternal PUFA status and offspring allergic diseases up to the age of 18 months.